Heimdall Insights

Global NTRK Fusion Gene Positive Advanced Solid Tumor Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global NTRK Fusion Gene Positive Advanced Solid Tumor Market was valued at $550 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.5% CAGR, to an estimated market size of $827 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The market encompasses diagnostic solutions and therapeutic agents specifically designed to target NTRK (Neurotrophic Tyrosine Receptor Kinase) gene fusions in patients with advanced solid tumors. This market is characterized by a tumor-agnostic treatment paradigm, where therapies are selected based on the presence of specific genetic driver mutations rather than the tumor's anatomical site or histological origin, primarily utilizing TRK inhibitors and Next-Generation Sequencing (NGS) for identification.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the NTRK Fusion Gene Positive Advanced Solid Tumor Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Therapeutics (TRK Inhibitors)
  • Diagnostics (NGS & IHC)